Ventilator-associated pneumonia
Pneumonia that occurs in people on mechanical ventilation
Ventilator-associated pneumonia (VAP) is a type of pneumonia that occurs in people who are on mechanical ventilation through an endotracheal tube or tracheostomy for at least 48 hours. It is a significant concern in intensive care units (ICUs) due to its association with increased morbidity and mortality.
Causes
VAP is caused by the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most common pathogens include bacteria such as Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The risk of VAP increases with the duration of mechanical ventilation.
Pathophysiology
The pathogenesis of VAP involves the aspiration of oropharyngeal secretions, colonization of the aerodigestive tract, and the formation of biofilms on the endotracheal tube. These factors contribute to the development of infection in the lower respiratory tract.
Diagnosis
The diagnosis of VAP is challenging and often involves a combination of clinical, radiological, and microbiological criteria. Common diagnostic tools include chest X-rays, bronchoalveolar lavage, and sputum cultures. The presence of new or progressive infiltrates on chest X-ray, along with clinical signs such as fever, purulent sputum, and leukocytosis, may suggest VAP.

Prevention
Preventive strategies for VAP include maintaining proper hand hygiene, elevating the head of the bed, daily sedation vacations, and implementing ventilator care bundles. The use of subglottic secretion drainage and selective digestive decontamination may also reduce the incidence of VAP.
Treatment
The treatment of VAP typically involves the administration of antibiotics tailored to the suspected or confirmed pathogens. Empirical therapy is often initiated based on local antibiograms and adjusted according to culture results. Supportive care, including adequate oxygenation and fluid management, is also crucial.
Prognosis
The prognosis of VAP varies depending on the patient's underlying condition, the causative organism, and the timeliness of appropriate treatment. VAP is associated with increased length of stay in the ICU and higher healthcare costs.
Related pages
References
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian